MAPT and Mental deterioration: Next, participants would be further triaged based on their plasma p-tau217 levels, where ‘low or negative’ participants would not undergo a tau-PET scan as their risk for future cognitive decline would be low, while ‘high or positive’ participants would undergo a tau-PET scan to further refine their risk profile44.